Paracetamol versus ibuprofen as required for fever or pain in the first year of life and the risk of eczema and bronchiolitis at age 1 year in New Zealand (PIPPA Tamariki): a multicentre, open-label, parallel-group, superiority, randomised controlled trial
Published in
The Lancet Child & Adolescent Health, January 2026
This research output has an Altmetric Attention Score of 132. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 August 2026.
All research outputs
#393,092
of 34,306,620 outputs
Outputs from The Lancet Child & Adolescent Health
#161
of 1,635 outputs
Outputs of similar age
#3,677
of 372,646 outputs
Outputs of similar age from The Lancet Child & Adolescent Health
#3
of 34 outputs
Altmetric has tracked 34,306,620 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,635 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 85.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 372,646 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.
